Filing Flows › Palisade Bio (PALI) › Recalls, complaints & regulation
Palisade Bio (PALI): clinical trials
Palisade Bio (PALI) beyond its filings: 2 active clinical trials.
Palisade Bio's latest quarter
Palisade Bio, Q2 2026: revenue $500K, net loss $10.6M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Palisade Bio have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.